Biopharma firms take advantage of welcoming IPO market

The biopharma sector has taken advantage of renewed interest from investors and welcoming financial markets, with 25 companies focused on developing new medicines successfully completing their IPOs on U.S., European and Australasia exchanges in the first half of the year – 20 percent more than the total who graduated to the public ranks this time last year.